Press Releases

Date	Title	Company
04-Jan-2023	Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders	Actimed Therapeutics
04-Jan-2023	The World of Biolog Gets Bigger! Biolog Adds Contract Services and New Analysis Software to Its Portfolio of Tools With the Acquisition of MIDI Labs and MIDI, Inc.	Newswire
04-Jan-2023	CD Bioparticles Announces Magnetofection Reagents for Gene Expression	CD Bioparticles
04-Jan-2023	CD Bioparticles Introduces Hydrophobic Interaction Chromatography Resins for Purification of Macromolecules	CD Bioparticles
04-Jan-2023	Availability of the Q4 Memorandum for modelling purposes	Sanofi
04-Jan-2023	WuXi STA Launches First Continuous Manufacturing Line for Oral Solids	WuXi STA
04-Jan-2023	Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers	Creative Diagnostics
04-Jan-2023	Creative Diagnostics Introduces New Hemagglutination Inhibition Assay Services	Creative Diagnostics
04-Jan-2023	Straumann Group appoints interim Chief Financial Officer	Straumann Holding AG
03-Jan-2023	Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio	Molecure
03-Jan-2023	Senior appointments at Copley signal the start of a new phase of growth	Copley
03-Jan-2023	Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01	Evaxion Biotech
03-Jan-2023	Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions	Alphalyse
03-Jan-2023	Dante Genomics to present at the 41st Annual J.P. Morgan Healthcare Conference	Dante Genomics
03-Jan-2023	Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab	Tiziana Life Sciences
03-Jan-2023	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference	iTeos Therapeutics
03-Jan-2023	PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro	PharmaSGP Holding SE
03-Jan-2023	Anatomic Pathology Market to achieve CAGR of 6.1% by 2032, owing to increasing incidence of cancer and other diseases \| insightSLICE	insightSLICE
03-Jan-2023	Primary Cell Market exhibiting CAGR of 9.2% by 2032, owing to rising investments in regenerative medicine research \| insightSLICE	insightSLICE
03-Jan-2023	Medical Cannula Market exhibiting CAGR of 7.2% by 2032, owing to increasing cases of diabetes & obesity \| insightSLICE	insightSLICE